These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 28044054

  • 1. Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report.
    Wendel C, Campitiello M, Plastino F, Eid N, Hennequin L, Quétin P, Longo R.
    Am J Case Rep; 2017 Jan 03; 18():7-11. PubMed ID: 28044054
    [Abstract] [Full Text] [Related]

  • 2. Skull Base Metastasis From Occult Renal Cell Carcinoma.
    Golinelli G, Toso A, Rosa MS, Valletti PA, Pia F.
    J Craniofac Surg; 2018 May 03; 29(3):e331-e333. PubMed ID: 29485573
    [Abstract] [Full Text] [Related]

  • 3. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
    Vogelzang NJ, Pal SK, Signorovitch JE, Reichmann WM, Li N, Yang C, Liu Z, Perez JR, Jonasch E.
    Curr Med Res Opin; 2016 May 03; 32(4):741-7. PubMed ID: 26744781
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
    Verzoni E, Grassi P, Montone R, Galli G, Necchi A, Procopio G.
    Tumori; 2015 May 03; 101(6):701-3. PubMed ID: 26108242
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The Complete Response to Targeted Drugs Without Surgery or Radiotherapy: A Case of Pituitary Metastasis From Renal Cell Carcinoma.
    Payandeh M, Sadeghi M, Sadeghi E.
    Acta Med Iran; 2016 Sep 03; 54(9):617-619. PubMed ID: 27832697
    [Abstract] [Full Text] [Related]

  • 11. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.
    Poprach A, Pavlik T, Melichar B, Kubackova K, Bortlicek Z, Svoboda M, Lakomy R, Vyzula R, Kiss I, Dusek L, Buchler T, Czech Renal Cancer Cooperative Group.
    Urol Oncol; 2014 May 03; 32(4):488-95. PubMed ID: 24321257
    [Abstract] [Full Text] [Related]

  • 12. Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline.
    Claret L, Zheng J, Mercier F, Chanu P, Chen Y, Rosbrook B, Yazdi P, Milligan PA, Bruno R.
    Cancer Chemother Pharmacol; 2016 Sep 03; 78(3):605-10. PubMed ID: 27468922
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
    Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B.
    J Clin Oncol; 2008 Jan 01; 26(1):127-31. PubMed ID: 18165647
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Barbastefano J, Garcia JA, Elson P, Wood LS, Lane BR, Dreicer R, Campbell SC, Rini BI.
    BJU Int; 2010 Nov 01; 106(9):1266-9. PubMed ID: 20346042
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
    Cao YW, Liu Y, Dong Z, Guo L, Kang EH, Wang YH, Zhang W, Niu HT.
    Urol Oncol; 2018 Jun 01; 36(6):311.e15-311.e25. PubMed ID: 29657088
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.